TY  - JOUR
A1  - Schlesinger, Tobias
A1  - Weißbrich, Benedikt
A1  - Wedekink, Florian
A1  - Notz, Quirin
A1  - Herrmann, Johannes
A1  - Krone, Manuel
A1  - Sitter, Magdalena
A1  - Schmid, Benedikt
A1  - Kredel, Markus
A1  - Stumpner, Jan
A1  - Dölken, Lars
A1  - Wischhusen, Jörg
A1  - Kranke, Peter
A1  - Meybohm, Patrick
A1  - Lotz, Christpher
T1  - Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study
JF  - PLoS One
N2  - Background
The viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).

Methods
This is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay.

Results
Most patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009).

Conclusions
COVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity.
KW  - viral load
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231348
VL  - 15, 2020
IS  - 11
ER  - 
TY  - JOUR
A1  - Beierle, Felix
A1  - Schobel, Johannes
A1  - Vogel, Carsten
A1  - Allgaier, Johannes
A1  - Mulansky, Lena
A1  - Haug, Fabian
A1  - Haug, Julian
A1  - Schlee, Winfried
A1  - Holfelder, Marc
A1  - Stach, Michael
A1  - Schickler, Marc
A1  - Baumeister, Harald
A1  - Cohrdes, Caroline
A1  - Deckert, Jürgen
A1  - Deserno, Lorenz
A1  - Edler, Johanna-Sophie
A1  - Eichner, Felizitas A.
A1  - Greger, Helmut
A1  - Hein, Grit
A1  - Heuschmann, Peter
A1  - John, Dennis
A1  - Kestler, Hans A.
A1  - Krefting, Dagmar
A1  - Langguth, Berthold
A1  - Meybohm, Patrick
A1  - Probst, Thomas
A1  - Reichert, Manfred
A1  - Romanos, Marcel
A1  - Störk, Stefan
A1  - Terhorst, Yannik
A1  - Weiß, Martin
A1  - Pryss, Rüdiger
T1  - Corona Health — A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic
JF  - International Journal of Environmental Research and Public Health
N2  - Physical and mental well-being during the COVID-19 pandemic is typically assessed via surveys, which might make it difficult to conduct longitudinal studies and might lead to data suffering from recall bias. Ecological momentary assessment (EMA) driven smartphone apps can help alleviate such issues, allowing for in situ recordings. Implementing such an app is not trivial, necessitates strict regulatory and legal requirements, and requires short development cycles to appropriately react to abrupt changes in the pandemic. Based on an existing app framework, we developed Corona Health, an app that serves as a platform for deploying questionnaire-based studies in combination with recordings of mobile sensors. In this paper, we present the technical details of Corona Health and provide first insights into the collected data. Through collaborative efforts from experts from public health, medicine, psychology, and computer science, we released Corona Health publicly on Google Play and the Apple App Store (in July 2020) in eight languages and attracted 7290 installations so far. Currently, five studies related to physical and mental well-being are deployed and 17,241 questionnaires have been filled out. Corona Health proves to be a viable tool for conducting research related to the COVID-19 pandemic and can serve as a blueprint for future EMA-based studies. The data we collected will substantially improve our knowledge on mental and physical health states, traits and trajectories as well as its risk and protective factors over the course of the COVID-19 pandemic and its diverse prevention measures.
KW  - mobile health
KW  - ecological momentary assessment
KW  - digital phenotyping
KW  - longitudinal studies
KW  - mobile crowdsensing
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242658
SN  - 1660-4601
VL  - 18
IS  - 14
ER  -